MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617099223 A) filed by The Johns Hopkins University on August 17, 2026, for Multivalent Dendrimer Conjugated Protacs For Cell-Targeted Targeted Protein Degradation.
Inventors include Rangaramanujam, Kannan; Liyanage, Wathsala; Kannan, Sujatha; and Kannan, Gokul.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: Conjugates containing hydroxylated polyamidoamines (hydroxyl PAMAMs) or a dendrimer formed of a sugar such as a glucose dendrimer and (i) elements of PROTAC or (ii) PROTACs,have been developed, which increase the efficacy of the PROTAC technology by increasing selective delivery to, and uptake at, sites of inflammation such as in the brain. The conjugates can be used for targeted intracellular delivery to degrade misfolded proteins and/or disease-associated proteins located in the cytosol, such that the conjugates can take advantage of a cell's intracellular protein degradation machinery.
Disclaimer: Curated by HT Syndication.
